Could a leukemia drug help treat rare lung disease LAM? new trial launches
NCT ID NCT06889168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial is testing the long-term safety of imatinib (Gleevec), a drug already approved for leukemia, in 20 women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Participants will take either imatinib or a placebo twice daily for 6 months, with regular check-ups. The goal is to see if imatinib is safe and tolerable over a longer period, building on earlier short-term results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imatinib (Gleevec)
- What this could lead to
- If successful, this could point toward a new treatment option for LAM, a rare lung disease, by showing that imatinib is safe and tolerable over 6 months.
- What could go wrong
- This is a very early, small phase 1 trial with only 20 participants, so results may not apply to everyone. The study focuses on safety, not yet on effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive TSC data and tissue bank opens to researchers
- Blood markers may guide LAM treatment dosing
- New PET scan could reveal early drug response in rare lung disease
- New registry tracks pregnancy risks in rare genetic disorders
- Could blood particles reveal secrets of rare lung disease LAM?
- Scientists dive deep into the roots of a mysterious lung disease